Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients

被引：0
|
作者：
Lena Klopp-Schulze
Markus Joerger
Sebastian G. Wicha
Rob ter Heine
Chantal Csajka
Zinnia P. Parra-Guillen
Charlotte Kloft
机构：
[1] Freie Universitaet Berlin,Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy
[2] Cantonal Hospital,Department of Medical Oncology and Haematology
[3] Radboud University Medical Centre,Department of Pharmacy
[4] University Hospital Center and University of Lausanne,Division of Clinical Pharmacology and Toxicology, Service of Biomedicine
[5] University of Hamburg,Institute of Pharmacy
来源：
Clinical Pharmacokinetics | 2018年 / 57卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：229 / 242
页数：13
相关论文
共 50 条
  • [41] Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
    P Saladores
    T Mürdter
    D Eccles
    B Chowbay
    N K Zgheib
    S Winter
    B Ganchev
    B Eccles
    S Gerty
    A Tfayli
    J S L Lim
    Y S Yap
    R C H Ng
    N S Wong
    R Dent
    M Z Habbal
    E Schaeffeler
    M Eichelbaum
    W Schroth
    M Schwab
    H Brauch
    The Pharmacogenomics Journal, 2015, 15 : 84 - 94
  • [42] Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
    Saladores, P.
    Muerdter, T.
    Eccles, D.
    Chowbay, B.
    Zgheib, N. K.
    Winter, S.
    Ganchev, B.
    Eccles, B.
    Gerty, S.
    Tfayli, A.
    Lim, J. S. L.
    Yap, Y. S.
    Ng, R. C. H.
    Wong, N. S.
    Dent, R.
    Habbal, M. Z.
    Schaeffeler, E.
    Eichelbaum, M.
    Schroth, W.
    Schwab, M.
    Brauch, H.
    PHARMACOGENOMICS JOURNAL, 2015, 15 (01): : 84 - 94
  • [43] Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models
    Jones, Calley J.
    Subramaniam, Malayannan
    Emch, Michael J.
    Bruinsma, Elizabeth S.
    Ingle, James N.
    Goetz, Matthew P.
    Hawse, John R.
    MOLECULAR CANCER RESEARCH, 2021, 19 (06) : 1026 - 1039
  • [44] Factors impacting tamoxifen use and adherence to therapy by older breast cancer patients
    Newell, D
    Freeman, J
    Rudkin-Minot, L
    Goodwin, J
    GERONTOLOGIST, 2002, 42 : 189 - 189
  • [45] Risk Factors for Tamoxifen-Induced Ovarian Hyperstimulation in Breast Cancer Patients
    Kim, Min Kyoon
    Shin, Hee-Chul
    CLINICAL BREAST CANCER, 2020, 20 (05) : 408 - 412
  • [46] CYP2D6 genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen.
    Balakrishnar, Bavanthi
    Menzies, Alexander M.
    Ali, Sayed Sahanawaz
    Yeap, Shang Heng
    Gao, Bo
    Liddle, Chris
    Coulter, Sally
    Provan, Pamela
    Gebski, Val
    Hui, Rina
    Kefford, Richard
    Wilcken, Nicholas
    Balleine, Rosemary L.
    Gurney, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Effect of tamoxifen on fibrinogen, D-dimer, lipid and lipoprotein concentrations in breast cancer patients
    Genç, S
    Tanrikulu-Kiliç, F
    Gürdöl, F
    Ünlüçerçi, Y
    Üler, P
    Lama, A
    Unur, N
    CLINICA CHIMICA ACTA, 2003, 337 (1-2) : 177 - 179
  • [48] The effect of rs5758550 on CYP2D6☆2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen
    Sanchez-Spitman, Anabel B.
    Moes, Dirk-Jan A. R.
    Gelderblom, Hans
    Dezentje, Vincent O.
    Swen, Jesse J.
    Guchelaar, Henk-Jan
    PHARMACOGENOMICS, 2017, 18 (12) : 1125 - 1132
  • [49] Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen
    Lee, Maria
    Piao, Jinlan
    Jeon, Myung Jae
    YONSEI MEDICAL JOURNAL, 2020, 61 (04) : 317 - 322
  • [50] EFFECT OF CYP3A4*22, CYP3A5*3 AND CYP3A COMBINED GENOTYPES ON ENDOXIFEN SERUM CONCENTRATIONS IN BREAST CANCER PATIENTS USING TAMOXIFEN.
    Spitman, A. B. Sanchez
    Moes, D. -J. A.
    Gelderblom, H.
    Dezentje, V. O.
    Swen, J. J.
    Guchelaar, H. -J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S48 - S48
12345